We are staying positive on Durect Corp. (DRRX) despite some recent setback and future challenges. Our investment thesis is based on the fact that we believe Remoxy will eventually receive approval in the U.S., and that management will secure another, potentially more lucrative, partnership on TRANSDUR-Sufentanil.
We are also optimistic on Posidur and believe that management will look to secure a partnership in the U.S. and Japan in 2009 or 2010. Finally, we are comfortable with the cash position given the current $42 million balance and all partnering opportunities available to management.
We continue to recommend investors Buy the stock. Our target remains $5 per share.Zacks Investment Research
